Data integrity is one of the central focal points of modern GMP inspections. Incomplete documentation, missing audit trails or inadequate access rights can have serious consequences. This article shows typical findings and practical measures for prevention.

Why data integrity is so important in the GMP world

Data integrity refers to the accuracy, completeness, consistency and availability of data throughout its entire lifecycle. In the pharmaceutical industry, it forms the basis for the evaluation of product quality, safety and efficacy. Incorrect or manipulated data can not only lead to regulatory consequences, but also pose a significant risk to patients.

The authorities are focussing in particular on the requirements of the ALCOA principle: Data must be replicable, legible, recorded in a timely manner, original and correct. Extended requirements such as ALCOA+ supplement these principles with criteria such as completeness, consistency and permanent availability.

Data integrity deficiencies are particularly critical in areas such as quality control, laboratory analysis, batch documentation and computerised systems. During a GMP inspection, auditors therefore specifically check whether companies have adequately safeguarded their GMP documentation and electronic systems.

Typical findings during GMP inspections

Among the most common issues are incomplete or subsequently altered data records. It is particularly problematic if changes are not documented or user activities are not clearly traceable. The absence of audit trails or electronic audit trails in computerised systems is considered a classic critical finding in this context.

Another common shortcoming concerns shared user accounts or inadequately regulated access rights. If several employees use the same access data, it is no longer possible to clearly trace who has made changes. This significantly limits traceability.

Deficiencies also occur regularly in paper-based processes. These include illegible entries, missing dates, subsequent corrections without justification, or the use of uncontrolled forms. Such deficiencies contravene the requirements of Good Documentation Practice.

Furthermore, regulatory authorities frequently criticise the inadequate training of staff in data integrity and GMP requirements. Even technically well-secured systems do not offer sufficient protection if processes are not implemented correctly.

Measures to prevent data integrity deficiencies

An effective approach to ensuring data integrity starts with clearly defined responsibilities and standard operating procedures (SOPs). Organisations should document all processes that affect the creation, processing, storage and archiving of data.

Computerised systems must be validated and regularly reviewed. Audit trails should be activated and evaluated routinely to detect unauthorised changes at an early stage. Equally important is a role-based access control system with individual user accounts and secure password policies.

Regular training plays a key role in raising staff awareness of data integrity and GMP documentation. This training should not only cover theoretical requirements but also provide practical examples of typical errors and deviations.

In addition, it is advisable to carry out internal audits and risk analyses. This allows potential weaknesses to be identified and corrected at an early stage, before they come to light during a regulatory GMP inspection.

Data integrity as an integral part of a sustainable quality system

Data integrity should not be viewed solely as a regulatory obligation, but as an integral part of a modern pharmaceutical quality system. In the long term, companies benefit from transparent processes, reliable data and improved traceability of all quality-related activities.

Regulatory requirements are constantly evolving. It is therefore important to regularly review existing systems and processes and adapt them to current regulatory expectations. Particularly in the context of digitalisation and the increasing automation of pharmaceutical processes, the safeguarding of electronic data is becoming increasingly important.

Those who consistently integrate data integrity into their day-to-day operations not only reduce the risk of critical GMP findings but also strengthen the confidence of regulatory authorities, business partners and patients in the quality of their own products.

Our specialist pharmaceutical interpreters support companies during GMP inspections, pharmaceutical production audits and international communication with regulatory authorities, using precise technical language. Professional pharmaceutical translations also help to ensure that quality-related documents are provided in multiple languages in a consistent, comprehensible and regulatory-compliant manner.

 

Image: Peaky Frames, unsplash.com